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Abstract  
The pharmaceutical and anticoagulant agent heparin, a member of the glycosaminoglycan family of carbo-
hydrates, has previously been identified as a potent inhibitor of a key Alzheimer’s disease drug target, the 
primary neuronal β-secretase, β-site amyloid precursor protein cleaving enzyme 1 (BACE1). The anticoag-
ulant activity of heparin has, however, precluded the repurposing of this widely used pharmaceutical as an 
Alzheimer’s disease therapeutic. Here, a glycosaminoglycan extract, composed predominantly of 4-sulfated 
chondroitin sulfate, has been isolated from Sardina pilchardus, which possess the ability to inhibit BACE1 
(IC50 [half maximal inhibitory concentration] = 4.8 μg/mL), while displaying highly attenuated anticoagu-
lant activities (activated partial thromboplastin time EC50 [median effective concentration] = 403.8 μg/mL, 
prothrombin time EC50 = 1.3 mg/mL). The marine-derived, chondroitin sulfate extract destabilizes BACE1, 
determined via differential scanning fluorimetry (ΔTm –5°C), to a similar extent as heparin, suggesting that 
BACE1 inhibition by glycosaminoglycans may occur through a common mode of action, which may assist 
in the screening of glycan-based BACE1 inhibitors for Alzheimer’s disease. 
Key Words: amyloid-β; aspartyl protease; carbohydrates; galactosaminoglycans; heparan sulfate; heparin; 
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Introduction 
The largest cause of dementia worldwide, Alzheimer’s dis-
ease (AD), results from the gradual cerebral atrophy of brain 
regions associated with learning and memory (Lane et al., 
2017). Existing therapeutics licensed for treatment are pal-
liative in nature, and do not target the underlying disease 
aetiology (Coimbra et al., 2018). It has therefore, become a 
focus to develop a therapeutic agent capable of targeting the 
underlying disease mechanisms of AD in order to preclude 
neurodegeneration before symptoms manifest.
In addition to the defining hallmarks of AD, amyloid-β 
(Aβ) plaques and intraneuronal neurofibrillary tangles 
(Querfurth and LaFerla, 2010), other pathophysiologies 
of AD include neurotransmitter depletion, apolipoprotein 
E polymorphism, oxidative stress, inflammation and mi-
tochondrial dysfunction. A common linked factor is the 
accumulation of Aβ peptides, the principal component of 
Aβ plaques (Rashid et al., 2018). Consequently, limiting the 
overproduction of Aβ has become an attractive target for 
halting AD. Aβ results from amyloid precursor protein (APP) 
metabolism through the amyloidogenic pathway, which 
commences by the catalytic action of the β-site amyloid 
precursor protein-cleaving enzyme 1 (BACE1). Cleavage of 
the resulting C-terminal APP fragment, β-carboxyl terminal 
fragment, by γ-secretase releases Aβ peptides of variable 
lengths into the extracellular space, where oligomerization 
can occur (Querfurth and LaFerla, 2010). Cleavage of APP 
by BACE1 is therefore, the rate-limiting step of Aβ produc-
tion, and as such has become a leading drug target for AD 
(Vassar, 2016; Coimbra et al., 2018). 
Glycosaminoglycans (GAGs) are anionic, linear hetero-
polysaccharides, which differ by the constituent disaccharide 
repeat units of either an uronic acid (D-glucuronic acid, 
GlcA or L-iduronic acid, IdoA), or D-galactose (Gal), and 
an amino sugar (D-galactosamine [GalN] or D-glucosamine 
[GlcN]) (Gandhi and Mancera, 2008). Structural differences 
between disaccharide repeat regions give rise to four main 
GAG classes: chondroitin sulfate (CS)/dermatan sulfate (DS), 
heparin/heparan sulfate (HS), keratan sulfate, and hyaluron-
ic acid (HA). Each monosaccharide within the disaccharide 
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unit may possess distinct degrees, and positions, of sulfation 
that dictate their biological activities (Powell et al., 2004), 
e.g., the potent anticoagulant activity of heparin, widely used 
as a clinical anticoagulant, is attributed principally to the 
pentasaccharide sequence [–4) α-D-GlcNS,6S (1–4) β-D-
GlcA (1–4) α-D-GlcNS,3S,6S (1–4) α-L-IdoA2S (1–4) α-D-
GlcNS,6S (1–] (Mulloy et al., 2016), although this example, 
does not typify the complexity of GAG structure-function 
relationships since several structures exhibit different levels 
of activity.
Previously, the GAGs HS and heparin have been identi-
fied as potent inhibitors of BACE1 (Scholefield et al., 2003; 
Patey et al., 2006, 2008; Schwörer et al., 2013; Zhang et al., 
2016). Low molecular weight GAGs have also been shown 
to possess the ability to cross the blood-brain barrier while 
retaining the ability to inhibit BACE1 (Leveugle et al., 1998; 
Patey et al., 2006), which proves a challenge for many small 
molecule inhibitors (Vassar, 2016). Despite this, the repur-
posing of heparin and low molecular weight derivatives (low 
molecular weight heparins) as a treatment for AD is largely 
prohibited by the likely side effect of anticoagulation. It has 
been demonstrated that simple chemical modifications can 
ablate the anticoagulant activity of heparin, while retaining 
favorable bioactivities such as BACE1 inhibition (Patey et al., 
2006, 2008). A number of polysaccharides have been isolated 
from marine species, which share the underlying disaccha-
ride backbone of GAGs, however, display unique structural 
modifications compared to their mammalian counterparts. 
As an account of the structural diversity of marine GAGs, 
many have been observed to possess favorable bioactivities 
while exhibiting a diminished effect on anticoagulation 
compared to mammalian heparin (Valcarcel et al., 2017; 
Mycroft-West et al., 2018). Furthermore, the therapeutic ex-
ploitation of these marine-GAGs may be advantageous over 
their mammalian counterparts due to religious beliefs, are 
unlikely to be contaminated by mammalian pathogens (e.g., 
spongiform encephalopathies), and can be acquired from 
aquaculture waste, making their exploitation economically, 
environmentally and socially appealing. Previously, a hep-
arin/HS-like GAG extracted from Portunus pelagicus, was 
demonstrated to inhibit BACE1 (Mycroft-West et al., 2019). 
Here, a further GAG extract, composed primarily 4-sulfated 
CS (CSA), isolated from Sardina pilchardus (S. pilchardus), 




The CSA containing, GAG extract from S. pilchardus was 
isolated essentially as described by Mycroft-West et al. (2019). 
Briefly 3.4 kg of S. pilchardus tissue (Oceana Group Compa-
ny Lucky Star, Cape Town, South Africa) was delipidated by 
homogenisation in excess acetone (VWR, Lutterworth, UK). 
After 24 hours, excess acetone was removed via centrifuga-
tion and the recovered tissue dried prior to protease diges-
tion (Alcalase®; Novozymes, Denmark) at 60°C for 24 hours. 
Glycosaminoglycan capture was facilitated using Amberlite 
ion exchange resin (IRA-900; Sigma-Aldrich, Dorset, UK; 
OH– form), which underwent extensive washes (1 M NaCl) 
prior to elution (3 M NaCl). Glycosaminoglycans were sub-
sequently precipitated (4°C for 48 hours) by the addition 
of methanol (1:1 v/v, 4°C; VWR, Lutterworth, UK) and de-
salted by dialysis utilizing a 3.5 kDa MWCO membrane (48 
hours; Biodesign, Carmel, NY, USA) against distilled H2O. 
The crude GAG extract was fractionated by DEAE-Sephacel 
(GE Healthcare, Buckinghamshire, UK) high-pressure, ion 
exchange liquid chromatograph (HPELC; Cecil Instruments, 
Cambridge, UK) post-filtration (0.2 µm, nylon syringe filter, 
Fisher Scientific, Loughborough, UK). Elution was per-
formed with a stepwise high pressure liquid chromatography 
(HPLC) grade sodium chloride gradient 0, 0.25, 0.5, 0.8, 1 
and 2 M NaCl (fractions F1–F6, respectively; Fisher Scientif-
ic) at a flow rate of 2 mL/min with inline UV-detection (λabs 
= 232 nm). Eluted fractions were extensively dialyzed against 
distilled H2O, utilizing a 3.5 kDa MWCO membrane (Biode-
sign) and subsequently lyophilized. Samples were stored at 
4°C until required.
Agarose gel electrophoresis
S. pilchardus extract (2–10 μg) alongside bona fide GAG 
standards (CSA, CSC, DS, heparin and HS) were subjected 
to electrophoretic separation using a 0.55% (w/v) agarose 
gel-based medium (80 × 80 × 1.5 mm) prepared in 50 mM 
1,3-diaminopropane-acetate (PDA) buffer, pH 9.0 (VWR), 
using a X-Cell SureLockTM Mini-Cell Electrophoresis Sys-
tem (ThermoFisher, Loughborough, UK). Electrophoresis 
was carried out for 30 minutes at 150 V, in PDA buffer, pH 
9.0. Fixation was performed using 0.1% (w/v, aqueous) 
cetyltrimethylammonium bromide (VWR) for 60 minutes 
prior to staining with 0.1% (w/v) toluidine blue (Fisher Sci-
entific) in acetic acid:ethanol: H2O (0.1:5:5, v/v). Gels were 
destained in the same solution, with the omission of tolui-
dine blue (Fisher Scientific) prior to processing using GIMP 
(v2.8, Berkeley, CA, USA) and ImageJ software (v1.51 (100), 
National Institutes of Health, Bethesda, MD, USA), as previ-
ously reported (Mycroft-West et al., 2019). 
Attenuated total reflectance fourier transform infrared 
spectroscopy 
The attenuated total reflectance fourier transform in-
frared (ATR-FTIR) spectra of lyophilized carbohydrate 
samples (5 mg) were recorded as reported in Devlin et al. 
(2019) using a Bruker Alpha I spectrometer (between 400 
to 4000 cm–1; 2/cm resolution) and have been presented 
as an average of 5 replicates (32 scans each). Background 
spectra were acquired prior to each sample and subtracted 
from the sample spectra in order to correct for features 
derived from the sampling environment. All ATR-FTIR 
spectra were processed using a Savitzky-Golay smoothing 
algorithm (R studio v1.1.463; signal package, sgolayfilter), 
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to a 2nd degree polynomial with 21 neighbours. Following 
smoothing baseline correction employing a 7th-order poly-
nomial was performed to negate any additional fluctuations 
in atmospheric conditions during sample spectra acquisi-
tion. Spectra were subsequently normalized between 0 and 
1 to account for any variation in sample quantity in contact 
with the ATR crystal. Spectral processing was conducted 
on an Asus Vivobook Pro fitted with an i7-7700HQ proces-
sor (M580VD-EB76, Taipet, Taiwan, China). The CO2 and 
H2O regions were omitted in order to negate environmental 
variability (2000–2500 cm–1, > 3600 cm–1 and < 700 cm–1), 
as described previously (Devlin et al., 2019; Mycroft-West 
et al., 2019). Spectra were subsequently analyzed using 
principal component analysis.
Circular dichroism
The circular dichroism spectra of S. pilchardus extract and 
bona fide GAG standards in HPLC grade H2O (10 mg/mL), 
were recorded (1 nm resolution, λ = 250 to 190 nm, 3 accu-
mulations) using a Jasco J-1100 spectrometer (JASCO, Inc., 
Oklahoma City, Oklahoma, USA) equipped with a quartz 
based sample-cell (0.2 mm path length; Hellma, Plainview, 
NY, USA) calibrated with (+)-10-camphorsulfonic acid 
(1 mg/mL). A baseline of HPLC grade H2O was recorded 
prior to sample acquisition, utilizing identical settings, and 
subtracted from sample spectra. Prior to statistical analysis 
using principal component, analysis spectra were normal-
ized to 250 nm. 
Nuclear magnetic resonance
Nuclear magnetic resonance (NMR) experiments were car-
ried out on the S. pilchardus CSA extract (5 mg in D2O; Alfa 
Aesar) at 298 K utilizing a Neo spectrometer (800-MHz; TCI 
cryoprobe; Bruker, Coventry, UK). Two-dimensional het-
eronuclear single-quantum coherence (1H–13C) spectra were 
recorded with standard gradient pulse sequences employing 
non-uniform sampling. Spectral processing was performed 
using TopSpin (Bruker). 
Förster resonance energy transfer
The S. pilchardus extract and porcine mucosal heparin 
(PMH) were screened for inhibitory against human β-secre-
tase (tag-free BACE1; ACRO Biosystems, Cambridge, MA, 
USA) utilizing a method modified from that of Patey et al. 
(2006) employing the principle of Förster resonance energy 
transfer (FRET). Human BACE1 (312.5 ng) was pre-incu-
bated with S. pilchardus CSA, PMH in sodium acetate buffer 
(50 mM, pH 4.0) at 37°C for 10 minutes, prior to addition 
of a quenched fluorogenic, peptide substrate, pre-incubated 
at 37°C (MCA-SEVNLDAEFRK[DNP]RR-NH2; 6.25 μM; 
Biomatik, Cambridge, Canada), to a final well volume of 100 
μL. Substrate only (containing no BACE1) and H2O controls 
were employed in order to define 100% and 0% inhibition, 
respectively. Fluorescent emission was monitored for 90 
minutes at λexc/emm = 320:405 nm on a Tecan Infinite® M200-
Pro plate reader (Tecan Group Ltd., Männedorf, Switzerland) 
equipped with i-controlTM. 
Differential scanning fluorimetry 
Differential scanning fluorimetry (DSF) was performed using 
the method of Uniewicz et al. (2010), post adaption from 
Niesen et al. (2007). S. pilchardus CSA, heparin (Celsus, Cin-
cinnati, OH, USA; maximum concentration of 200 μg/mL) 
or H2O were incubated with human BACE1 (1 μg) with 20 
× Sypro Orange (Invitrogen), in 50 mM sodium acetate, pH 
4.0 to make a final volume of 40 μL in 96-well qPCR plates 
(AB Biosystems, Warrington, UK). ∆RFu was monitored on 
a StepOne plus qPCR machine (AB Biosystems) using the 
TAMRA filter, thermal melt curves were recorded between 
20–90°C with an initial incubation phase of 2 minutes at 
20°C, before increasing + 0.5°C increments every 30 seconds. 
Activated partial thromboplastin time
S. pilchardus extract, PMH samples (25 μL) or control (H2O, 
HPLC grade) were mixed prior to incubation with normal 
human plasma (50 μL, pooled & citrated; Technoclone, Sur-
rey, UK) and Pathromtin SL (50 μL; Siemens, Erlangen, Ger-
many) at 37°C for 120 seconds in advance of the addition of 
CaCl2 (50 mM; 25 μL, Alfa Aesar, Heysham, UK). The time 
taken for clot formation was noted using a coagulometer 
(Thrombotrak Solo; 120 second upper maximum for 100% 
clotting; Axis-Shield) as described by Mycroft-West et al. 
(2019). Mucosal heparin (porcine, 193 IU/mg; Celsus) and 
HPLC-grade H2O (clotting time of 37–40 seconds, repre-
senting 0% inhibition) were used as controls. 
Prothrombin time
S. pilchardus extract, PMH (50 μL) or H2O control (HPLC 
grade were mixed prior to incubation with normal human 
plasma (50 μL, pooled & citrated; Technoclone) at 37°C for 
60 seconds in advance of the insertion of Thromborel S (50 
μL; Siemens). The time taken for clot formation was not-
ed using a coagulometer (Thrombotrak Solo, Axis-Shield, 
Dundee, UK; 120-second upper maximum for 100% clot-
ting;) as described by Mycroft-West et al. (2019). Mucosal 
heparin (porcine, 193 IU/mg; Celsus) and HPLC-grade H2O 
(clotting time of 13–14 seconds, representing 0% inhibition) 
were used as controls. 
Statistical analysis
Principal component analysis was applied to normalized 
FTIR and circular dichroism spectra, using the singular 
value decomposition (SVN), base prcomp function in R 
(v1.1.463, R studio Inc. Boston, MA, USA; installed upon 
an Asus Vivobook Pro fitted with an i7-7700HQ processor 
M580VD-EB76) as described previously (Devlin et al 2019; 
Mycroft-West et al., 2019). The matrices of intensities were 
mean-centred, with no additional scaling. Scree plots indicat-
ed the principal components displaying the greatest variance.
Percentage BACE1 inhibition for FRET assays were cal-
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culated by determining fluorescence change (∆RFu/min) 
for all samples within the linear-range of the 0% inhibition 
control. Percentage inhibition was subsequently calculated 
relative to ∆RFu/min of 0 and 100% inhibition controls (n 
= 3; ± SD). Data has been fitted using non-linear regression 
(four-parameter logistics model) to determine IC50 values, 
using GraphPad Prism 7 (GraphPad Software, San Diego, 
CA, USA).
Melting temperatures (Tm) of BACE1 were determined 
by smoothing melt curves (19 neighbours, Savitzky-Golay 
2nd order polynomial) obtained from DSF experiments and 
plotting the first derivative (GraphPad Prism 7). The peak 
maxima of the first-derivative plots (Tm; n = 3; ± SD) were 
determined using MatLab (R20018a; MathWorks, Cam-
bridge, UK).
EC50s for activated partial thromboplastin time (aPTT) 
and prothrombin time (PT) assays (n = 3; ± SD) were ob-
tained using Prism 7 (sigmoidal, dose response; GraphPad 
Software). 
Results
Isolation and characterization of a chondroitin sulfate A 
extract from S. pilchardus 
A crude GAG extract was obtained from S. pilchardus by 
proteolytic digestion, as previously described (Mycroft-West 
et al., 2019), and subsequently isolated with anion-exchange 
chromatography (Sephacel DEAE) employing a NaCl, step-
wise gradient. The eluate obtained in the 800 mM NaCl frac-
tion (F4), was analyzed by agarose-based, electrophoresis 
using a PDA buffer system. Fraction 4 (F4) of the S. pilchar-
dus GAG extract possessed comparable electrophoretic mi-
gration to that of chondroitin and/or dermatan sulfate (DS). 
The bands observed did not correspond with the migration 
of mammalian heparin or HS (Figure 1). 
The ATR-FTIR spectrum of S. pilchardus F4 was compared 
with that of a library of bone fide GAGs using principal com-
ponent analysis (Figure 2). PC1 and PC2 were compared 
(comprising 72% of the variance), separating S. pilchardus F4 
into the CSA containing region, which is distinct from other 
GAGs (Figure 2B).
Principal component analysis was further employed to 
compare the circular dichroism spectra of S. pilchardus F4 
with that of known GAGs (Figure 3). Glycosaminoglycan 
circular dichroism spectra are particularly sensitive to uronic 
acid conformation (Rudd et al., 2009), while CS and DS dif-
fer in their composition incorporating either GlcA or IdoA, 
respectively. Heparin also contains higher levels of IdoA 
relative to HS (Meneghetti et al., 2015). Comparison of PC1 
(covering 87.6% of the total variance) separated S. pilchardus 
F4 away from heparin/HS samples and into a region along-
side CS/DS. While comparison of PC1 versus PC2 (covering 
97.4% of the total variance) further separates CS from DS 
samples, with S. pilchardus F4 aligning within the CS cluster. 
S. pilchardus F4 was confirmed to be predominantly CSA 
by two-dimensional heteronuclear single quantum coher-
ence NMR. Spectra revealed the principal N-acetyl region 
(1H) at 2.02 ppm, corresponding to that of CS (Gardini et 
al., 2017) with a minor peak at 2.08 ppm (1H) also observed, 
characteristic of DS (Gardini et al., 2017) (Figure 4). Inte-
gration of the N-acetyl stretches corresponding to CS and 
DS indicated that the GAG component of S. pilchardus F4 
is composed of > 95% CS. Furthermore, integration of the 
regions corresponding to A2 and A6 indicated that the S. 
pilchardus F4 sample contained sulfation at predominantly 
the C4 position of the N-acetyl galactosamine residue. Mi-
nor peaks that could be associated to other GAGs and/or 
different CS substitution pattern are also observed but these 
are of very low intensity. Together, the data suggest that S. 
pilchardus F4 is CSA-like in nature and from herein, will be 
referred to as a S. pilchardus CSA extract.
A CSA extract from S. pilchardus inhibits the human 
β-secretase, BACE1 
The BACE1 inhibitory potential of both the S. pilchardus 
CSA extract and PMH (with known inhibitory activity) was 
assayed using FRET (Scholefield et al., 2003; Patey et al., 
2006; Mycroft-West et al., 2019). The S. pilchardus CSA ex-
tract exhibited maximal inhibition at concentrations greater 
than 10 µg/mL; IC50 = 4.8 µg/mL with an R2 of 0.93, approx-
imately 2-fold lower than that of PMH (IC50 = 2.6 µg/mL; R2 
= 0.97, Figure 5). Chondroitin sulfate has previously been 
reported to possess only weak BACE1 inhibitory activity 
by Scholefield et al. (2003), however, the specific structural 
composition, in regards of the total sulfation level or pattern, 
has not been reported.
Human β-secretase (BACE1) is destabilized by the 
presence of the S. pilchardus CSA extract 
DSF was utilized to determine whether the extract form S. 
pilchardus CSA altered the thermal stability of BACE1 in a 
similar fashion to PMH (Mycroft-West et al., 2019). A 1:4 
ratio (w/w) of BACE1:PMH the thermal stability of BACE1 
decreased by ΔTm = –10.5°C (± 0.5 SD, n = 3), in line with 
previous reports (Figure 6A) (Mycroft-West et al., 2019). In 
contrast, in the presence of the S. pilchardus CSA extract at 
the same w/w ratio (1:4, BACE1:S. pilchardus CSA) the ΔTm 
of BACE1 = –5°C (± 1.3 SD, n = 3), an approximately 2-fold 
reduction in the level of thermal destabilization compared 
to that of PMH. The destabilization of BACE1 by both PMH 
and the S. pilchardus CSA extract demonstrated concentra-
tion dependence (Figure 6B). 
The S. pilchardus CSA extract exhibits negligible aPTT 
and PT anticoagulation activities 
The anticoagulant activity of heparin would appear to pre-
clude its use as a pharmaceutical against alternative dis-
ease states such as AD. With the exception of chemically 
over-sulfated chondroitin sulfate, native CS possesses negli-
gible anticoagulant activity compared to that of mammalian 
heparin (Hogwood et al., 2018). To verify this, the activities 
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of S. pilchardus CSA in the aPTT (intrinsic pathway) and PT 
(extrinsic pathway) assays were examined against the known 
clinical anticoagulant, PMH (193 IU/mg). S. pilchardus CSA 
displayed a > 200 fold reduction in the aPTT (Figure 7A) 
with an EC50 of 403.8 μg/mL compared to PMH (EC50 = 
1.6 μg/mL) and greater than an 80 fold reduction in the PT 
(Figure 7B) with an EC50 of 1.3 mg/mL when compared to 
PMH (EC50 = 14.8 μg/mL). Both coagulation assays indicate 
that the S. pilchardus CSA possesses negligible anticoagulant 
activity. 
Discussion
The GAG extract obtained from S. pilchardus was identified 
to have comparable electrophoretic migration to that of CS/
DS when subject to agarose-based, PDA buffered, gel elec-
trophoresis. Further spectroscopic analysis of the S. pilchar-
dus extract suggested that the major GAG composition falls 
within that of CS, with the FTIR further aligning towards CS 
sulfated predominantly at the C4 position (CSA). Two-di-
mensional heteronuclear single quantum coherence NMR, 
revealed that the principal N-acetyl signal corresponded to 
that of CS, with the majority of the CS component contain-
ing 4-O-sulfated GalNAc residues. Minor spectral features 
were also observed but, with very low intensity, suggesting 
they account for < 5% of the extract. 
The S. pilchardus CSA extract exhibited inhibitory poten-
tial against BACE1 in a manner similar to PMH albeit at a 
slightly diminished level, as demonstrated by the IC50 (deter-
mined via dose-response FRET assays). This is in contrast to 
previous observations that CS does not exhibit BACE1 inhib-
itory activity above ~20%, however, the fine structure of the 
CS was not reported in this study (Scholefield et al., 2003). 
This indicates that BACE1 inhibitory activity of CS may re-
quire sulfation at defined positions rather than as a result of 
total anionic charge, as previously identified for HS/heparin 
(Patey et al., 2006). A decrease in the thermal stability of 
BACE1, was also observed by DSF (Tm values) in the pres-
ence of PMH or the S. pilchardus CSA extract, as previously 
reported for the glucosaminoglycans (Mycroft-West et al., 
2019). The ability of heparin and the S. pilchardus CSA ex-
tract to promote thermal destabilization of BACE1 occurred 
with a concentration-dependent response similar to that of 
the inhibitory potential in FRET-based assays. A comparable 
two-fold decrease in the IC50 required for BACE1 inhibition 
(FRET) and in ∆Tm (DSF) was observed in the presence of 
S. pilchardus CSA extract compared to PMH. This suggests 
that the mode of BACE1 inhibition by the GAG category 
of carbohydrates may involve structural destabilization, in 
contrast to other known BACE1 inhibitors, for which stabi-
lization has been reported using the same technique (Lo et 
al., 2004). Destabilization of BACE1 by GAGs would appear 
to be linked directly to BACE1 inhibitory potential, for this 
class of molecules. 
The repurposing of heparin-derived pharmaceuticals as 
potential BACE1 inhibitors, or for other alternative ther-
apeutics is largely precluded by significant anticoagulant 
potential owing to its inhibition of the human coagulation 
cascade, primarily through antithrombin III. With the nota-
ble exception of over-sulfated chondroitin sulfate, which is 
not naturally occurring, CS exhibits negligible anticoagulant 
activity in comparison to mammalian heparin (Hogwood 
et al., 2018). The anticoagulant potential of the S. pilchardus 
CSA extract was, therefore, examined using the aPTT and 
PT coagulation assays, which are widely used to examine the 
intrinsic or extrinsic pathways, respectively. It should be not-
ed that both assays incorporate the common pathway. The S. 
pilchardus CSA extract displayed highly attenuated activity 
compared to PMH in both the aPTT and PT assays. Despite 
the slightly diminished BACE1 inhibitory activity of the S. 
pilchardus CSA extract in comparison to unmodified PMH, 
the therapeutic value is greater when anticoagulation activ-
ity is taken into account. In addition to heparin, CS is also 
available as either an over the counter neutraceutical (USA) 
or, as a prescribed drug under the European Medical Agen-
cy for the treatment of osteoarthritis (Herotin et al., 2010). 
Current CS drugs are considered to show no significant side 
effects (Herotin et al., 2010), in contrast to heparin pharma-
ceuticals, whose well-known side effect is heparin-induced 
thrombocytopenia. In addition, CS has been reported to be 
bioavailable through oral and subcutaneous routes (for re-
view of the pharmacokinetic properties of CS see Heroti et 
al., 2010), whereas heparin is not absorbed after oral admin-
istration without the requirement of additional formulations 
(Mousa et al., 2014). The development of a CS based ther-
apeutic for AD may therefore offer additional advantages 
over other GAGs, and small peptide inhibitors, which have 
unfavorable pharmacokinetic properties (Vassar, 2016). 
The utilization of marine derived GAGs for the discovery 
of novel bioactive compounds is advantageous over other 
mammalian sources currently being explored (for both hep-
arin and CS therapeutics), as many marine species such as, S. 
pilchardus overcome religious mores and are free from mam-
malian pathogens (e.g., spongiform encephalopathies, swine 
viruses). Glycosaminoglycans can also be obtained readily 
from marine aquaculture waste material and in some cases 
can be farmed in a controlled aquaculture environment, 
making their exploitation economically and environmentally 
favorable, whilst constituting a sustainable source of biolog-
ically active glycans. The exploitation of marine species as 
a novel source of bioactive GAGs is therefore an attractive 
alternative to the mammalian sources that are currently uti-
lized to obtain GAGs for therapeutic use. 
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Figure 1 Separation of the crude S. pilchardus glycosaminoglycan extract by anion-exchange chromatography and agarose-based gel electrophoresis.
(A) Anion exchange chromatogram of crude S. pilchardus glycosaminoglycan extract. Fractions 1–6 (denoted F1–6) were eluted with a NaCl gradient (dashed 
line) with elution monitored at λAbs of 232 nm (solid line). (B) Electrophoretic mobility of the glycosaminoglycan (GAG) extract from S. pilchardus (F4; 800 
mM) compared against bona fide glycosaminoglycans of heparin, heparan sulfate (HS), chondroitin sulfate A (CSA), C (CSC) and D (CSD), and dermatan 
sulfate (DS). Mix = chondroitin sulfate A, heparin and heparan sulfate mixture.  
Figure 2 Attenuated total reflection Fourier-transform infrared spectrum of the crude S. pilchardus glycosaminoglycan extract.
(A) Chondroitin sulfate A (black) and S. pilchardus (red) attenuated total reflection Fourier-transform infrared spectra, n = 5. (B) Principal component anal-
ysis Score Plot (PC1 vs. PC2) of S. pilchardus compared against a bone fide glycosaminoglycan library. Heparan sulfate (cyan), heparin (blue), chondroitin 
sulfate with composition not stated (black, open circles), chondroitin sulfate A (black filled circles), chondroitin sulfate C (grey), dermatan sulfate (orange), 
over-sulfated chondroitin sulfate (magenta), hyaluronic acid (green), S. pilchardus glycosaminoglycans (red filled circles).  
Figure 3 Circular dichroism spectrum of the crude S. pilchardus glycosaminoglycan extract. 
(A) Circular dichroism spectra of chondroitin sulfate A (black) and S. pilchardus (red). (B) Principal component analysis Score Plot (PC1 v. PC2) of S. 
pilchardus compared against a bone fide glycosaminoglycan library. Heparan sulfate (cyan), chondroitin sulfate (black), chondroitin sulfate A (black filled 
circles), heparin (blue), dermatan sulfate (orange), over sulfated chondroitin sulfate (magenta), hyaluronic acid (green), S. pilchardus glycosaminoglycan (red 
filled circle).  
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Figure 4 Nuclear magnetic resonance spectra (heteronuclear single 
quantum coherence) for S. pilchardus F4. 
Chondroitin sulfate-associated major signals are indicated. Spectral inte-
gration was carried out using labelled signals. A: Galactosamine; U: uronic 
acid. Minor peaks are observed but with low intensity meaning that their 
abundance is lower than 5%. F1 and F2 are the indirect and direct dimen-
sions, respectively.
Figure 5 Inhibition of human beta-site amyloid precursor protein 
cleaving enzyme 1, by S. pilchardus chondroitin sulfate A (blue) or 
porcine mucosal heparin (black) as determined by Förster resonance 
energy transfer. 
Porcine mucosal heparin IC50 = 2.6 µg/mL with an R2 of 0.97; S. pilchardus 
chondroitin sulfate A extract IC50 = 4.8 µg/mL with an R2 of 0.93. GAG: 
Glycosaminoglycan; IC50: half maximal inhibitory concentration.
Figure 6 Differential scanning fluorimetry profile for the S. pilchardus chondroitin sulfate A extract. 
(A) Thermal stability (first differential) profile of β-site amyloid precursor protein cleaving enzyme 1 (1 µg; black) and with 4 µg porcine mucosal heparin 
(green) or 4 µg S. pilchardus chondroitin sulfate A extract (blue), measured by differential scanning fluorimetry in 50 mM, pH 4.0, NaOAc buffer. ΔTm of β-site 
amyloid precursor protein cleaving enzyme 1 with 4 µg of porcine mucosal heparin (*** –10.5°C ± 0.5 SD, n = 3) or 4 µg S. pilchardus chondroitin sulfate A 
extract (** –5°C ± 1.3 SD, n = 3). (B) ΔTm of beta-site amyloid precursor protein cleaving enzyme 1 alone (black) or in the presence of increasing concentra-
tions of porcine mucosal heparin or S. pilchardus chondroitin sulfate A extract. 
Figure 7 Anticoagulation 
profiles for the S. pilchardus 
chondroitin sulfate A extract. 
Inhibitory response of heparin 
(circle, solid line) or S. pilchardus 
chondroitin sulfate A (square, 
dashed line) (mean % response, n 
= 3; ± SD) of (A) activated partial 
thromboplastin time (porcine 
mucosal heparin EC50 = 1.6 μg/
mL, S. pilchardus chondroitin sul-
fate A EC50 = 403.8 μg/mL) and (B) 
Prothrombin time (porcine mu-
cosal heparin EC50= 14.8 μg/mL, 
S. pilchardus chondroitin sulfate A 
EC50 = 1.3 mg/mL).
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